Q-omics provides the consensus-scored ROCK1P1 profile across patient tissues and cancer cell-line models. ROCK1P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ROCK1P1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ROCK1P1 RNA expression shows 17,220 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, HNSC, and THYM as cancer lineages where ROCK1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ROCK1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ROCK1P1 survival associations across molecular data types. ROCK1P1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ROCK1P1 RNA expression–survival associations across cancer types. High ROCK1P1 expression shows unfavorable associations in LUAD, CHOL and UCEC, but favorable associations in SKCM, UCS and ACC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for ROCK1P1 RNA expression.
This table summarizes ROCK1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ROCK1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ROCK1P1 shows higher tumor expression in HNSC, BRCA, CHOL, LIHC, LUAD and LUSC. The HNSC box plot shows higher ROCK1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.349, t-test p < 0.001).
This table shows molecular features associated with ROCK1P1 in patient tissues and cancer cell lines. In patient samples, ROCK1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ROCK1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
